NEW YORK (GenomeWeb News) – EMD Millipore and Proteomic International have signed a collaborative agreement to validate biomarkers related to diabetic nephropathy, the firms said today.
Under the agreement, Australia-based Proteomic International, which uses mass spectrometry for drug discovery and contract research services, will assess 13 newly identified protein biomarkers using EMD Millipore's multiplex immunoassays. The biomarkers include proteins that are involved in metabolism, inflammation, and oxidative stress.
According to the firms, the biomarkers can better represent disease prediction and progression than the current single-marker test that is used for diabetic nephropathy.
In addition to validating the 13 markers already selected, Proteomics International will use clinical specimens from its sample repository to assess additional biomarkers developed by EMD Millipore.
"In addition to their biomarkers, Proteomics International brings access to large, highly stratified patient cohorts in Australia to validate assay performance," Jehangir Mistry, director of R&D at Billerica, Mass.-based EMD Millipore, said in a statement. "This will help us determine the clinical utility of the biomarkers for development of potential diagnostic tests for diabetic nephropathy."
Financial and other terms of the collaboration were not disclosed.